Warrior Met Coal, Inc. Common Stock (HCC) is currently showing a slightly bearish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: There is a mild negative lean in the higher-value headlines, though the setup is not strong enough to call decisively bearish.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
41/100
Slightly Bearish
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$81.85
Trend Context
Mixed / range
Latest briefing
What's happening with HCC
businesswire.com15 Jul 2026
Warrior Sets Date for Second Quarter 2026 Earnings Announcement and Investor Conference Call
BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its second quarter 2026 investor conference call at 4:30 p.m. ET on Wednesday, August 5, 2026. Warrior will release its results following the close of market trading that afternoon. To participate in the conference call, please call 1-844-340-9047 (domestic) or 1-412-858-5206 (international) 10 minutes prior to the start time and reference the Warrior Met Coal conference call. A w.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com9 Jul 2026
HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Pursue Nasdaq Listing
Transaction expected to provide HCC Healthcare with access to public capital markets to accelerate growth in integrated medical and long-term care services across Asia Transaction expected to provide HCC Healthcare with access to public capital markets to accelerate growth in integrated medical and long-term care services across Asia
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
gurufocus.com10 Jun 2026
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational i
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
gurufocus.com
9 Jun 2026
Warrior Met Coal Inc (HCC) Shares Fall 4.3% -- What GF Score of 81 Tells Investors
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
